良性前立腺増殖の治療のためのソー・パメットー抽出物:体系的なレビュー
1Department of Veterans Affairs Coordinating Center of the Cochrane Collaborative Review Group in Prostatic Diseases and Urologic Malignancies, Minneapolis Veterans Affairs Medical Center, Minn 55417, USA. wilt.timothy@minneapolis.va.gov
JAMA
|November 20, 1998
まとめ
ソーパルメット (Serenoa repens) 抽出物は,良性前立腺増殖 (BPH) の症状を効果的に治療し,尿路の流れを改善します. この植物抽出物は,フィナステリドと同様の利点を提供していますが,副作用が少なく,BPH管理の実行可能な選択肢となっています.
科学分野:
- 泌尿器科 泌尿器科とは
- 薬理学 薬理学とは
- フィトセラピーは植物療法です.
背景:
- 良性前立腺増殖 (BPH) は,高齢の男性における一般的な疾患で,下部尿路の症状を引き起こします.
- ソー・パメット (Serenoa repens) は,BPHの症状に対する広く使用されているハーブ・レメディです.
- BPHに対するSerenoa repensの有効性と安全性に関する証拠は,体系的な評価を必要とします.
研究 の 目的:
- 症状のあるBPHの男性におけるSerenoa repensの治療効果と安全性を体系的にレビューし,メタ分析する.
- Serenoa repensの効果をプラセボとフィナステリドと比較するために.
主な方法:
- 2939人の男性を対象とした18件のランダム化対照試験 (RCT) の体系的レビューとメタ解析.
- 含有基準:症状のあるBPH,Serenoa repensの介入,プラセボまたは薬理学的対照,および30日以上の治療期間.
- データ抽出には,研究設計,参加者の特徴,治療の割り当て,およびアウトカムが含まれていました; 16の研究はダブルブラインドでした.
主要な成果:
- プラセボと比較して,Serenoa Repensは,尿路症状スコア,ニクチュリア,尿流量ピークを大幅に改善しました.
- Serenoa repensの有効性は,泌尿器の症状と流れを改善する点でフィナステリドと同等でした.
- 副作用は軽度で,Serenoa repensでは稀であり,フィナステリドよりも勃起不全の割合が低い.
結論:
- セレノア・レペンスは,BPHの男性における泌尿器科症状とフロー測定の改善における治療効果を示しています.
- フィナステリドと比較して,Serenoa repensは,より良い安全性プロファイルを持つ同様の利点を提供しています.
- 長期の有効性と合併症の予防を確認するために,標準化製剤に関するさらなる研究が必要である.
関連する概念動画
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...


